Zymeworks Inc. (NYSE:ZYME) Shares Sold by Compagnie Lombard Odier SCmA

Compagnie Lombard Odier SCmA trimmed its position in shares of Zymeworks Inc. (NYSE:ZYME) by 30.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,000 shares of the company’s stock after selling 3,000 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Zymeworks were worth $102,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in Zymeworks by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock valued at $1,667,000 after purchasing an additional 650 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Zymeworks by 6.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock valued at $214,000 after purchasing an additional 940 shares in the last quarter. FMR LLC grew its holdings in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after purchasing an additional 1,525 shares in the last quarter. Stifel Financial Corp grew its holdings in Zymeworks by 2.1% during the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock valued at $924,000 after purchasing an additional 1,540 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Zymeworks by 13.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,695 shares of the company’s stock valued at $193,000 after purchasing an additional 2,653 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on ZYME. HC Wainwright reiterated a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Stifel Nicolaus increased their price objective on shares of Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Wells Fargo & Company increased their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Leerink Partnrs upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Finally, Citigroup increased their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.17.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock in a transaction dated Friday, January 17th. The shares were bought at an average cost of $13.87 per share, for a total transaction of $273,904.76. Following the transaction, the director now owns 15,720,161 shares in the company, valued at $218,038,633.07. This represents a 0.13 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul Andrew Moore sold 21,200 shares of Zymeworks stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the completion of the sale, the insider now owns 14,741 shares in the company, valued at approximately $219,935.72. This represents a 58.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have acquired 603,539 shares of company stock worth $8,384,708 and have sold 89,601 shares worth $1,336,847. Insiders own 1.92% of the company’s stock.

Zymeworks Stock Performance

Zymeworks stock opened at $15.01 on Friday. The firm’s 50-day moving average is $14.13 and its 200-day moving average is $13.27. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The company has a market cap of $1.03 billion, a P/E ratio of -10.01 and a beta of 1.10.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.